Verastem, Inc. (VSTM) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $5.09: Risk below floor (2.8 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 10.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Elevated put/call ratio: 20.60; Below-average business quality.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor... Read more
Sell if holding. Engine safety override at $5.09: Risk below floor (2.8 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 10.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Elevated put/call ratio: 20.60; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 69. Score 5.5/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-08Recent Developments — Verastem, Inc.
Latest news
- NEWS RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14 — benzinga Jul 7, 2026 positive
Generated 2026-07-08T21:03:53Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 7.6% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.09: Risk below floor (2.8 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 10.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Elevated put/call ratio: 20.60; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 69. Prior stop was $4.72. Score 5.5/10, moderate confidence.
Take-profit target: $13.05 (+156.9% upside). Prior stop was $4.72. Stop-loss: $4.72.
Risk below floor (2.8 < 3.0).
Verastem, Inc. trades at a P/E of N/A (forward -4.2). TrendMatrix value score: 7.2/10. Verdict: Sell.
15 analysts cover VSTM with a consensus score of 4.3/5. Average price target: $15.
What does Verastem, Inc. do?Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the...
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.